Literature DB >> 16041520

Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock.

Jorge Ibrain Figueira Salluh, Guilherme Alvarenga Feres, Eduardo Velasco, Gustavo S Holanda, Luisa Toscano, Marcio Soares.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16041520     DOI： 10.1007/s00134-005-2725-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Parenteral ivermectin in Strongyloides hyperinfection.

Authors:  P L Chiodini; A J Reid; M J Wiselka; R Firmin; J Foweraker
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

2.  [Treatment of experimental infection by Strongyloides venezuelensis in rats, with the use of injectable ivermectin and levamisole].

Authors:  R Campos; P L Pinto; V Amato Neto; L Matsubara; A Miyamoto; S A de Carvalho; C K Takiguti; A A Moreira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1989 Jan-Feb       Impact factor: 1.846

3.  Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease?

Authors:  Jorge I F Salluh; Fernando A Bozza; Tatiana S Pinto; Luisa Toscano; Peter F Weller; Marcio Soares
Journal:  Braz J Infect Dis       Date:  2006-01-06       Impact factor: 1.949

Review 4.  Antiparasitic drugs.

Authors:  L X Liu; P F Weller
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

Review 5.  Strongyloides stercoralis in the Immunocompromised Population.

Authors:  Paul B Keiser; Thomas B Nutman
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132
  5 in total
  5 in total

Review 1.  Human infection with Strongyloides stercoralis and other related Strongyloides species.

Authors:  Thomas B Nutman
Journal:  Parasitology       Date:  2016-05-16       Impact factor: 3.234

2.  CATMAT statement on disseminated strongyloidiasis: Prevention, assessment and management guidelines.

Authors:  A K Boggild; M Libman; C Greenaway; A E McCarthy
Journal:  Can Commun Dis Rep       Date:  2016-01-07

Review 3.  Severe strongyloidiasis: a systematic review of case reports.

Authors:  Dora Buonfrate; Ana Requena-Mendez; Andrea Angheben; Jose Muñoz; Federico Gobbi; Jef Van Den Ende; Zeno Bisoffi
Journal:  BMC Infect Dis       Date:  2013-02-08       Impact factor: 3.090

4.  Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.

Authors:  Carlos Chaccour; Gloria Abizanda; Ángel Irigoyen-Barrio; Aina Casellas; Azucena Aldaz; Fernando Martínez-Galán; Felix Hammann; Ana Gloria Gil
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

Review 5.  Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.

Authors:  Cesar Henriquez-Camacho; Eduardo Gotuzzo; Juan Echevarria; A Clinton White; Angelica Terashima; Frine Samalvides; José A Pérez-Molina; Maria N Plana
Journal:  Cochrane Database Syst Rev       Date:  2016-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.